This presentation is an extension of the already made presentation before, that deals with RNTCP guidelines for some special aspects encountered during tuberculosis management, other than management of individual diagnoses alone.
Have a look!
Catridge based nucleic acid amplification test(CBNAAT) / RIF assay gene xpert POWER PONT. other normal tests versus CBNAAT. issues for cbnaat by WHO & CONCLUSION.
Hello Guys,
This presentation consists of the updated guidelines under National tuberculosis elimination programme of India (MOHFW). The presentation includes case definitions and diagnostic algorithms for Pulmonary, Extrapulmonary and Drug resistant TB(MDR/ XDR TB) and the tratment protocols in pediatric cases.
Hope you find it useful.
The bacteria that cause tuberculosis (TB) can develop resistance to the antimicrobial drugs used to cure the disease. Multidrug-resistant TB (MDR-TB) is TB that does not respond to at least isoniazid and rifampicin, the 2 most powerful anti-TB drugs.
The 2 reasons why multidrug resistance continues to emerge and spread are mismanagement of TB treatment and person-to-person transmission. Most people with TB are cured by a strictly followed, 6-month drug regimen that is provided to patients with support and supervision. Inappropriate or incorrect use of antimicrobial drugs, or use of ineffective formulations of drugs (such as use of single drugs, poor quality medicines or bad storage conditions), and premature treatment interruption can cause drug resistance, which can then be transmitted, especially in crowded settings such as prisons and hospitals.
In some countries, it is becoming increasingly difficult to treat MDR-TB. Treatment options are limited and expensive, recommended medicines are not always available, and patients experience many adverse effects from the drugs. In some cases even more severe drug-resistant TB may develop. Extensively drug-resistant TB, XDR-TB, is a form of multidrug-resistant TB with additional resistance to more anti-TB drugs that therefore responds to even fewer available medicines. It has been reported in 117 countries worldwide.
Drug resistance can be detected using special laboratory tests which test the bacteria for sensitivity to the drugs or detect resistance patterns. These tests can be molecular in type (such as Xpert MTB/RIF) or else culture-based. Molecular techniques can provide results within hours and have been successfully implemented even in low resource settings.
New WHO recommendations aim to speed up detection and improve treatment outcomes for MDR-TB through use of a novel rapid diagnostic test and a shorter, cheaper treatment regimen. At less than US$ 1000 per patient, the new treatment regimen can be completed in 9–12 months. Not only is it less expensive than current regimens, but it is also expected to improve outcomes and potentially decrease deaths due to better adherence to treatment and reduced loss to follow-up.
Solutions to control drug-resistant TB are to:
cure the TB patient the first time around
provide access to diagnosis
ensure adequate infection control in facilities where patients are treated
ensure the appropriate use of recommended second-line drugs.
In 2015, an estimated 480 000 people worldwide developed MDR-TB, and an additional 100 000 people with rifampicin-resistant TB were also newly eligible for MDR-TB treatment. India, China, and the Russian Federation accounted for 45% of the 580 000 cases. It is estimated that about 9.5% of these cases were XDR-TB.
Catridge based nucleic acid amplification test(CBNAAT) / RIF assay gene xpert POWER PONT. other normal tests versus CBNAAT. issues for cbnaat by WHO & CONCLUSION.
Hello Guys,
This presentation consists of the updated guidelines under National tuberculosis elimination programme of India (MOHFW). The presentation includes case definitions and diagnostic algorithms for Pulmonary, Extrapulmonary and Drug resistant TB(MDR/ XDR TB) and the tratment protocols in pediatric cases.
Hope you find it useful.
The bacteria that cause tuberculosis (TB) can develop resistance to the antimicrobial drugs used to cure the disease. Multidrug-resistant TB (MDR-TB) is TB that does not respond to at least isoniazid and rifampicin, the 2 most powerful anti-TB drugs.
The 2 reasons why multidrug resistance continues to emerge and spread are mismanagement of TB treatment and person-to-person transmission. Most people with TB are cured by a strictly followed, 6-month drug regimen that is provided to patients with support and supervision. Inappropriate or incorrect use of antimicrobial drugs, or use of ineffective formulations of drugs (such as use of single drugs, poor quality medicines or bad storage conditions), and premature treatment interruption can cause drug resistance, which can then be transmitted, especially in crowded settings such as prisons and hospitals.
In some countries, it is becoming increasingly difficult to treat MDR-TB. Treatment options are limited and expensive, recommended medicines are not always available, and patients experience many adverse effects from the drugs. In some cases even more severe drug-resistant TB may develop. Extensively drug-resistant TB, XDR-TB, is a form of multidrug-resistant TB with additional resistance to more anti-TB drugs that therefore responds to even fewer available medicines. It has been reported in 117 countries worldwide.
Drug resistance can be detected using special laboratory tests which test the bacteria for sensitivity to the drugs or detect resistance patterns. These tests can be molecular in type (such as Xpert MTB/RIF) or else culture-based. Molecular techniques can provide results within hours and have been successfully implemented even in low resource settings.
New WHO recommendations aim to speed up detection and improve treatment outcomes for MDR-TB through use of a novel rapid diagnostic test and a shorter, cheaper treatment regimen. At less than US$ 1000 per patient, the new treatment regimen can be completed in 9–12 months. Not only is it less expensive than current regimens, but it is also expected to improve outcomes and potentially decrease deaths due to better adherence to treatment and reduced loss to follow-up.
Solutions to control drug-resistant TB are to:
cure the TB patient the first time around
provide access to diagnosis
ensure adequate infection control in facilities where patients are treated
ensure the appropriate use of recommended second-line drugs.
In 2015, an estimated 480 000 people worldwide developed MDR-TB, and an additional 100 000 people with rifampicin-resistant TB were also newly eligible for MDR-TB treatment. India, China, and the Russian Federation accounted for 45% of the 580 000 cases. It is estimated that about 9.5% of these cases were XDR-TB.
Standards for TB care in India, RNTCP challenges: India, Maharashtra & Mumbai...Amol Patil
This presentation contains TB statistics- Global, India, Maharashtra and Mumbai till 2015.
Details of TB control strategies will be covered in Subsequent parts.
High prevalence of DR-TB (drug-resistant tuberculosis): An Indicator of publi...Madiha Mushtaque
Tuberculosis (TB) is among the 10 most common worldwide causes of mortality. In Pakistan, estimated 510,000 tuberculosis patients had been diagnosed with an occurrence of 276/100,000. As per most recent global TB report 2018, Pakistan is amongst the 30 countries high TB with drug-resistant Mycobacterium tuberculosis particularly MDR (multi-drug resistant strains). A retrospective study had been designed using DR-TB patients’ records from January 2013 to the December 2017 year from a public sector hospital in Karachi. Overall 315 drug-resistant tuberculosis patient’s data had been incorporated in the study. All data had been analyzed using SPSS version 16 software. Chi-square test had been used to analyze the data with CI (confidence interval) 95% and level of significance 5%. The study result showed that 64.1% MDR patients, 27.9% MTB rifampicin resistance, 4.8% mono-drug resistant , XDR(1.6%), 1% poly-drug resistant and only 0.6% are MDR suspects showing no association of DR-TB with gender (p-value 0.787), age group (p-value 0.757), treatment outcomes (p-value 0.549), year of registration( p-value 0.206), first line treatment history(p-value 0.643) with a 95% confidence interval. The drug resistance TB cases have been periodically rising every year. Early identification is required to reduce the percent mortality and inhibit the disease transmission.
New faces of tuberculosis: new chellenges requiring new solutionsJean Jacques Bernatas
TB reflects poverty, and while it accompanies Humankind for 70,000 years, this disease presents new faces for which new solutions must be implemented to move towards TB elimination by 2030. Finally a better coordination between all stakeholders is instrumental for winning this fight.
RNTCP guidelines for tuberculosis management by RxVichuZ! RxVichuZ
This powerpoint deals with RNTCP guidelines for TB management. Chiefly grouping of drugs for therapeutic utilities, cases involving RR-TB,INH-resistant TB,MDR-TB, CDR-TB,PDR-TB and Mono drug resistant TB management strategies has been elucidated in precise form.
updated statistics about antimicrobial resistance,causes and mechanism of antimicrobial resistances, national antimicrobial policy, national antimicrobial surveillance, new delhi b metallo-lactamase-1 bacteria
This presentation deals with pathophysiology of Parkinson's Disease.
Important headings, including normal physiology, etiological factors and clinical manifestations have been elucidated.
This powerpoint, deals with HIV pathophysiology, signs and symptoms, mode of transmission and diagnostic parameters.
Purely based on clinical pharmacist perspective.
This presentation deals with buprenorphine drug profile, from a clinical pharmacist perspective.
Summarized version of drug, including chief ADRs, interactions, and patient and health-care professional counselling tips have been mentioned.
This PDF deals with important catchpoints regarding the use of 5-alpha reductase inhibitors, their safety and efficacy stats, and important counselling tips.
This PDF deals with important guidelines, with respect to usage of antibiotics. This PDF outlines the important strategies involved while using antibiotics, and important factors involving antibiotic selection.
This word document deals with summarized drug profile of cotrimoxazole. Important pharmacological headings, along with important counselling tips and drug catchpoints have also been elucidated.
This is my first word document, converted into pdf format!
This document deals with AMOXICILLIN drug profile in brief.
It includes significant pharmacological headings, including an additional heading, stating important catchpoints with respect to amoxicillin!
Food drug interactions with penicillins: by RxVichuZ!RxVichuZ
This is my 107th powerpoint...it deals with significant drug-food interactions when taking specific penicillins.
This is my first powerpoint that deals with drug interactions.
Do support!
Snake bite poisoning and its treatment by RxVichuZ!RxVichuZ
My 106th powerpoint...that deals with snake bite poisoning.
Different types of venomous snakes, their characteristics, envenomation features and treatment strategies have been explained in a summary.
Hope it is effective for the readers involved.
This powerpoint is a case presentation, that explains the case of ADCHF, with comorbidities, comprising HTN, CAD and DLP.
A summary on the recent advancements in HF management, along with justification of therapy provided, has been elucidated.
A note on home remedies and counselling tips has also been provided.
Directly acting antivirals and Visceral Leishmaniasis: A case reportRxVichuZ
This presentation deals with visceral leishmaniasis induced by directly acting antivirals in a patient with Hepatitis C infection.
Case details in summary, along with case report publication details have been summarized.
References have been provided below each slide.
...and this is my 100th powerpoint.....!!
Sincerely thanking everyone who have supported me in my journey till now :) :)
This powerpoint deals with drug mnemonics, easy to remember mnemonics, that can be helpful for easy memory of some aspects of Pharmacology!!
Happy reading!!
Acute coronary syndrome management by RxVichuZ! ;)RxVichuZ
This is my 99th powerpoint...
Deals with ACS(Acute coronary syndrome), its clinical features, and management strategies, based on standard guidelines and literatures.
Journal club presentation: by RxVichuZ!! ;)RxVichuZ
My 97th powerpoint... deals with the comparative study of efficacy of piperacillin-tazobactam, as compared to meropenem in the treatment of ESBL(Extended spectrum beta-lactamases) infections.
A summarized insight has been provided, using research article from JAMA.
PPI-INDUCED BICYTOPENIA: MATTER OF CONCERN by RxVichuZ! ;)RxVichuZ
This presentation deals with bicytopenia induced by proton pump inhibitors, that were reported and published as a Case Report by researchers from China.
References have been provided as a separate textbox under each slide, for extensive referencing into the same.
Dipeptidyl peptidase inhibitors(DPP-IV): A deep insightRxVichuZ
This presentation deals with DPP-IV inhibitors, that are implicated for use in diabetes mellitus. Generalized pharmacology, including a precise insight into individual drugs have been elucidated.
Principles of cancer chemotherapy: a deep insight by RxVichuZ!RxVichuZ
This powerpoint deals with principles of cancer chemotherapy, that includes headings regarding cancer definition, its etiology, diagnostic measures and general considerations to be observed while initiating anti-cancer regimens in patients.
Sulfonylureas for Diabetes: A deep insightRxVichuZ
This powerpoint presentation solely deals with Sulfonylureas, that come under Insulin secretagogues. Their complete pharmacological profile, with pharmacovigilance parameters, important catchpoints and mnemonics have been explained.
This word document deals with the drug profile of amikacin. Important headings, with respect to its pharmacology, along with a note on important dosage regimens and antimicrobial spectrum, have also been mentioned, with reference to standard textbooks, guidelines and relevant articles.
These lecture slides, by Dr Sidra Arshad, offer a quick overview of physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar leads (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
Knee anatomy and clinical tests 2024.pdfvimalpl1234
This includes all relevant anatomy and clinical tests compiled from standard textbooks, Campbell,netter etc..It is comprehensive and best suited for orthopaedicians and orthopaedic residents.
Prix Galien International 2024 Forum ProgramLevi Shapiro
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMEN’S HEALTH: FERTILITY PRESERVATION
- WHAT’S NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
RNTCP guidelines for tuberculosis management: Extended version
1. PRESENTED TO: DR. SASWATI SINHA
PRESENTED BY:
(DR.)VISHNU.R.NAIR,
PHARM.D INTERN(AMRI HOSPITAL ACADEMIC TRAINEE),
NATIONAL COLLEGE OF PHARMACY, KERALA.
2. GENERAL INTRODUCTION
EPIDEMIOLOGICAL STATISTICS
CLASSIFICATION OF ATDs(RNTCP CONCEPT)
CLASSIFICATION OF TB-CASES(RNTCP CONCEPT)
MANAGEMENT OF DRUG-SENSITIVE TB
MANAGEMENT OF MDR-TB(PRINCIPLES INVOLVED)
MANAGEMENT OF RR-TB
MANAGEMENT OF MONODRUG RESISTANT TB
MANAGEMENT OF PDR-TB
MANAGEMENT OF INH-RESISTANT TB
MANAGEMENT OF XDR-TB
TREATMENT OF PATIENTS WITH ADRs to ATDs
DELAMANID: A NEW INTRODUCTION IN INDIA
4. Full form: “Revised National Tuberculosis Control Program”
State-run TB control initiative of the Indian Government
Main objective of RNTCP : “To implement WHO guidelines for TB &
DOTS therapy strategy in Indian scenario”
Revised National Tuberculosis Control Programme: NATIONAL STRATEGIC PLAN FOR TUBERCULOSIS ELIMINATION 2017–2025.Available from
https://tbcindia.gov.in/WriteReadData/NSP%20Draft%2020.02.2017%201.pdf [Last accessed on January 22, 2019].
Tripathi K. Essentials of medical pharmacology. 8th ed. New Delhi: Jaypee Brothers Medical Publishers; 2018.
6. According to World Health Organization (WHO) estimates(2015):
- 10.4 million individuals developed active disease
- More than 1.8 million deaths occurred
- TB stands among top 10 causes of death worldwide.
According to the United States Centers for Disease Control and Prevention
(CDC) statistics:
- One-third of the world's population is infected with TB
- TB represents a leading killer of individuals infected with HIV.
WHO Global Tuberculosis Report 2018. Available at https://www.who.int/news-room/fact-sheets/detail/tuberculosis. Last accessed on January 23, 2019.
7. Tuberculosis (TB) is one of the top 10 causes of death worldwide.
In 2017, 10 million people fell ill with TB, and 1.6 million died from the disease (including
0.3 million among people with HIV).
In 2017, an estimated 1 million children became ill with TB and 2,30,000 children died of TB
(including children with HIV associated TB).
TB is a leading killer of HIV-positive people.
Multidrug-resistant TB (MDR-TB) remains a public health crisis and a health security threat.
WHO estimates that there were 5,58,000 new cases with resistance to rifampicin – the most
effective first-line drug, of which 82% had MDR-TB.
Globally, TB incidence is falling at about 2% per year.
An estimated 54 million lives were saved through TB diagnosis and treatment between 2000
and 2017.
Ending the TB epidemic by 2030 is among the health targets of the Sustainable Development
Goals.
WHO Global Tuberculosis Report 2018. Available at https://www.who.int/news-room/fact-sheets/detail/tuberculosis. Last accessed on January 23, 2019.
8. MDR-TB has a rapid course, with worse outcomes
In India MDR-TB constitutes:
a. 3% of all new TB-cases
b. 17% of retreatment cases
According to WHO global report(2015) India has the HIGHEST NUMBER of MDR-TB
cases!(Approx. 71,000 cases annually)
In 2015,the World Health Organization (WHO) estimated 480,000 incident multidrug resistant
TB (MDR-TB; resistance of both isoniazid and rifampin) cases globally.
With an estimated 79,000 MDR-TB cases India along with the Russian Federation and
South Africa accounted for 45% of the total notified combined MDR-TB and rifampin-
resistant (RR-TB) cases in 2015
World Health Organization. The Global Tuberculosis Report: 2016. Geneva,Switzerland: WHO, 2016. Available at http://www.who.int/tb/publications/global_report/
en/. Last accessed 2019, January 23.
10. According to RNTCP guidelines ATDs(Anti-tubercular drugs) have been classified into 5
groups, to facilitate proper management of the disease
Groups include:
A. GROUP I(1st line oral drugs):
- Most potent
- Best tolerated oral drugs
- Used routinely
- Drugs include isoniazid(H), rifampin(R), pyrazinamide(Z) & ethambutol (E)
- Use code “RIPE” to remember drug names in this category!
Revised National Tuberculosis Control Programme: NATIONAL STRATEGIC PLAN FOR TUBERCULOSIS ELIMINATION 2017–2025.Available from
https://tbcindia.gov.in/WriteReadData/NSP%20Draft%2020.02.2017%201.pdf [Last accessed on January 22, 2019].
Tripathi K. Essentials of medical pharmacology. 8th ed. New Delhi: Jaypee Brothers Medical Publishers; 2018.
11. B. GROUP II(Injectable drugs):
- Potent
- Bactericidal
- Injectables in nature
- Chiefly include aminoglycosides like Streptomycin(S), Amikacin(Am), Kanamycin(Km) &
Capreomycin
- Use code “SACK” to remember names of drugs in this category!
Revised National Tuberculosis Control Programme: NATIONAL STRATEGIC PLAN FOR TUBERCULOSIS ELIMINATION 2017–2025.Available from
https://tbcindia.gov.in/WriteReadData/NSP%20Draft%2020.02.2017%201.pdf [Last accessed on January 22, 2019].
Tripathi K. Essentials of medical pharmacology. 8th ed. New Delhi: Jaypee Brothers Medical Publishers; 2018.
12. C. GROUP III (FLUOROQUINOLONES):
- Well-tolerated
- Bactericidal
- Oral drugs
- According to RNTCP guidelines all patients with drug-resistant TB
SHOULD RECEIVE ONE FLUOROQUINOLONE!
- Drugs include Ofloxacin, Levofloxacin, Ciprofloxacin and Moxifloxacin
- Use code “CLOM” to remember names of drugs under this category!
Revised National Tuberculosis Control Programme: NATIONAL STRATEGIC PLAN FOR TUBERCULOSIS ELIMINATION 2017–2025.Available from
https://tbcindia.gov.in/WriteReadData/NSP%20Draft%2020.02.2017%201.pdf [Last accessed on January 22, 2019].
Tripathi K. Essentials of medical pharmacology. 8th ed. New Delhi: Jaypee Brothers Medical Publishers; 2018.
13. D. GROUP IV(2nd line oral drugs):
- Less-effective
- Bacteriostatic
- More toxic than 1st line oral agents!
- Drugs include ethionamide, prothionamide, cycloserine, terizidone, PAS, rifabutin and
rifapentine.
- Use code “PP-RR-ECT” to remember name of drugs in this category!
E. GROUP V(Unclear efficacy drugs):
- Drugs with unclear efficacy(Use code “CCC-LIB” to remember name of drugs in this
category!)
- Not recommended for MDR-TB!
- May be used as RESERVE DRUGS (in XDR-TB)!
- Drugs include bedaquiline, clarithromycin, clofazimine, linezolid, co-amoxiclav and
imipenem-cilastatin.
Revised National Tuberculosis Control Programme: NATIONAL STRATEGIC PLAN FOR TUBERCULOSIS ELIMINATION 2017–2025.Available from https://tbcindia.gov.in/WriteReadData/NSP%20Draft%2020.02.2017%201.pdf [Last
accessed on January 22, 2019].
Tripathi K. Essentials of medical pharmacology. 8th ed. New Delhi: Jaypee Brothers Medical Publishers; 2018.
15. For selection of appropriate ATT(Anti-tubercular therapy) RNTCP(2016) has classified TB
cases into:
A. DRUG-SENSITIVE TB:
- In this case patient’s bacilli susceptible to all 1st line drugs
- Such patients may include:
i. Newly-diagnosed patients
ii. Patients, pre-treated with TB in past
B. MULTI-DRUG RESISTANT TB(MDR-TB):
- In this case patient’s bacilli resistant to BOTH RIFAMPIN & INH!
- May/may not be resistant to other 1st line ATDs
Revised National Tuberculosis Control Programme: NATIONAL STRATEGIC PLAN FOR TUBERCULOSIS ELIMINATION 2017–2025.Available from
https://tbcindia.gov.in/WriteReadData/NSP%20Draft%2020.02.2017%201.pdf [Last accessed on January 22, 2019].
Tripathi K. Essentials of medical pharmacology. 8th ed. New Delhi: Jaypee Brothers Medical Publishers; 2018.
16. C. RIFAMPIN-RESISTANT TB(RR-TB):
- In this case patient’s bacilli resistant to ONLY RIFAMPIN & NOT INH!
- May/may not be resistant to other ATDs.
D. MONO-DRUG RESISTANT TB:
- In this case patient’s bacilli resistant to ANY ONE 1st line ATD(Except rifampin)
E. POLYDRUG-RESISTANT TB(PDR-TB):
- In this case patient’s bacilli resistant to MORE THAN ONE 1ST LINE ATD(except
rifampin & INH)
F. EXTENSIVE DRUG RESISTANT TB(XDR-TB):
- In this case patient’s bacilli resistant to a FQ & a 2nd line injectable ATD!
Revised National Tuberculosis Control Programme: NATIONAL STRATEGIC PLAN FOR TUBERCULOSIS ELIMINATION 2017–2025.Available from
https://tbcindia.gov.in/WriteReadData/NSP%20Draft%2020.02.2017%201.pdf [Last accessed on January 22, 2019].
Tripathi K. Essentials of medical pharmacology. 8th ed. New Delhi: Jaypee Brothers Medical Publishers; 2018.
18. Usually treated by 1st line ATDs
Drug-sensitive TB includes 2 types:
A. Newly-treated patients:
- Treatment involves:
2 months of HRZE(Intensive phase) + 4 months of HRE(Continuation phase)
- Total duration: 6 months
B. Previously-treated patients:
- Treatment involves:
[2 months of HRZES + 1 month of HRZE](Intensive phase) + 5 months of HRE(Continuation
phase)
- Total duration: 8 months.
Revised National Tuberculosis Control Programme: NATIONAL STRATEGIC PLAN FOR TUBERCULOSIS ELIMINATION 2017–2025.Available from
https://tbcindia.gov.in/WriteReadData/NSP%20Draft%2020.02.2017%201.pdf [Last accessed on January 22, 2019].
Tripathi K. Essentials of medical pharmacology. 8th ed. New Delhi: Jaypee Brothers Medical Publishers; 2018.
19. TYPE OF PATIENT INTENSIVE PHASE CONTINUATION
PHASE
TOTAL DURATION
New 2 months of HRZE 4 months of HRE 6 months
Previously-treated
patients
2 months of HRZES +
1 month of HRZE
5 months of HRE 8 months
Revised National Tuberculosis Control Programme: NATIONAL STRATEGIC PLAN FOR TUBERCULOSIS ELIMINATION 2017–2025.Available from
https://tbcindia.gov.in/WriteReadData/NSP%20Draft%2020.02.2017%201.pdf [Last accessed on January 22, 2019].
Tripathi K. Essentials of medical pharmacology. 8th ed. New Delhi: Jaypee Brothers Medical Publishers; 2018.
21. MDR-TB has a rapid course, with worse outcomes
Treatment involves complex multiple 2nd line drug regimens, which
confer the following demerits:
a. Longer treatment duration
b. Expensive
c. High risk of toxicity!!
Tripathi K. Essentials of medical pharmacology. 8th ed. New Delhi: Jaypee Brothers Medical Publishers; 2018.
22. General principles of MDR-TB management
a. Include 4 effective drugs in regimen(6 drugs can also be included, provided
efficacy regarding any of them is uncertain; back-up!)
b. Avoid usage of cross-resistance drugs, chiefly:
- 2 FQs
- Kanamycin with Amikacin
- Ethionamide with prothionamide
- Cycloserine with terizidone
- Ethionamide with INH(low-level resistance)
c. When selecting drugs for treatment select in a hierarchical order, for
example:
2 Group I drugs( Z, E) + one injectable drug(Group II) + One FQ(Group III) + 2 Group IV
drugs.
Revised National Tuberculosis Control Programme: NATIONAL STRATEGIC PLAN FOR TUBERCULOSIS ELIMINATION 2017–2025.Available from
https://tbcindia.gov.in/WriteReadData/NSP%20Draft%2020.02.2017%201.pdf [Last accessed on January 22, 2019].
Tripathi K. Essentials of medical pharmacology. 8th ed. New Delhi: Jaypee Brothers Medical Publishers; 2018.
23. d. Standard RNTCP regimen for MDR-TB consists of :
- 6 drugs in “intensive phase”(for 6-9 months)
- 4 drugs in “continuation phase”(for 18 months)
e. Minimal 6 month of intensive phase can be extended by 1 month each
time(to a total maximum of 9 months) provided, sputum culture at 4th , 5th &
6th months of intensive phase turns out to be positive
f. Pyridoxine (at dose of 100 mg/day) should be given to all patients during
therapy to avoid precipitation of neurotoxicity(attributed to ATDs)!
Revised National Tuberculosis Control Programme: NATIONAL STRATEGIC PLAN FOR TUBERCULOSIS ELIMINATION 2017–2025.Available from
https://tbcindia.gov.in/WriteReadData/NSP%20Draft%2020.02.2017%201.pdf [Last accessed on January 22, 2019].
Tripathi K. Essentials of medical pharmacology. 8th ed. New Delhi: Jaypee Brothers Medical Publishers; 2018.
24. INTENSIVE PHASE(6-9 MONTHS) CONTINUATION PHASE(18 MONTHS)
Kanamycin(Km) Levofloxacin (Lfx)
Levofloxacin (Lfx) Ethionamide(Eto)
Ethionamide(Eto) Cycloserine(Cs)
Cycloserine(Cs) Ethambutol(E)
Pyrazinamide(Z)
Ethambutol(E)
STANDARD RNTCP REGIMEN FOR MDR-TB
N.B: Pyridoxine (100 mg/day) should also be added to above regimen
Tripathi K. Essentials of medical pharmacology. 8th ed. New Delhi: Jaypee Brothers Medical Publishers; 2018.
26. According to both WHO & RNTCP(2016) RR-TB is treated as MDR-TB
Since patients with RR-TB are sensitive to INH INH is also added to “intensive phase”
Thus, RNTCP management strategy for RR-TB includes:
INTENSIVE PHASE(6-9 MONTHS) CONTINUOUS PHASE(18 MONTHS)
Kanamycin(Km) Levofloxacin(Lfx)
Levofloxacin(Lfx) Ethionamide(Eto)
Ethionamide(Eto) Cycloserine(Cs)
Cycloserine(Cs) Ethambutol(E)
Pyrazinamide(Z) INH
Ethambutol(E)
INH
Revised National Tuberculosis Control Programme: NATIONAL STRATEGIC PLAN FOR TUBERCULOSIS ELIMINATION 2017–2025.Available from https://tbcindia.gov.in/WriteReadData/NSP%20Draft%2020.02.2017%201.pdf [Last
accessed on January 22, 2019].
Tripathi K. Essentials of medical pharmacology. 8th ed. New Delhi: Jaypee Brothers Medical Publishers; 2018.
N.B: Add pyridoxine (100 mg/day) to the above regimen
28. MANAGEMENT STRATEGY
INTENSIVE PHASE(3-6 MONTHS) CONTINUATION PHASE(6 MONTHS)
Rifampin + two of 1st line drugs(sensitive to bacilli)
+ one injectable 2nd line drug + 1 fluoroquinolone
Total of 5 drugs, to be given in intensive phase.
- Stop injectable drug
- Continue with remaining 4 drugs for 6 months.
Revised National Tuberculosis Control Programme: NATIONAL STRATEGIC PLAN FOR TUBERCULOSIS ELIMINATION 2017–2025.Available from
https://tbcindia.gov.in/WriteReadData/NSP%20Draft%2020.02.2017%201.pdf [Last accessed on January 22, 2019].
Tripathi K. Essentials of medical pharmacology. 8th ed. New Delhi: Jaypee Brothers Medical Publishers; 2018.
N.B: Add pyridoxine (100 mg/day) to the above regimen.
30. MANAGEMENT STRATEGY
INTENSIVE PHASE(3-6 MONTHS) CONTINUATION PHASE(6 MONTHS)
Rifampin + one injectable 2nd line drug + one
fluoroquinolone + any 1st line drug (to which bacilli
is sensitive) + one of the oral 2nd line
drugs(Ethionamide/ Cycloserine/ PAS)
Total of 5 drugs to be used in continuation phase.
• Stop injectable drug
• Continue remaining 4 drugs.
Revised National Tuberculosis Control Programme: NATIONAL STRATEGIC PLAN FOR TUBERCULOSIS ELIMINATION 2017–2025.Available from
https://tbcindia.gov.in/WriteReadData/NSP%20Draft%2020.02.2017%201.pdf [Last accessed on January 22, 2019].
Tripathi K. Essentials of medical pharmacology. 8th ed. New Delhi: Jaypee Brothers Medical Publishers; 2018.
N.B: Add Pyridoxine(100 mg/day) to the above treatment regimen.
32. In order to strategize treatment for INH-resistant TB firstly an insight into mechanisms of
INH-resistance is important
INH resistance can occur in 2 ways:
A. LOW-LEVEL INH RESISTANCE:
- inhA gene plays role in activity of NAD-dependent enoyl-acyl carrier protein reductase
- In low-level INH resistance mutation occurs in the inhA gene
- In such situations:
i. Focus on using HIGH DOSE OF INH (900 mg/day, for average body weight of 46-70 kg)
ii. Add pyridoxine to treatment regimen
iii. Monitor for potential neurotoxicity
iv. Avoid concurrent usage of Ethionamide(since it won’t be effective in low-level INH resistance)!
Revised National Tuberculosis Control Programme: NATIONAL STRATEGIC PLAN FOR TUBERCULOSIS ELIMINATION 2017–2025.Available from https://tbcindia.gov.in/WriteReadData/NSP%20Draft%2020.02.2017%201.pdf [Last
accessed on January 22, 2019].
Tripathi K. Essentials of medical pharmacology. 8th ed. New Delhi: Jaypee Brothers Medical Publishers; 2018.
33. B. HIGH-LEVEL INH RESISTANCE:
- KatG gene encodes for enzyme catalase peroxidase helps in conversion
of INH to its active metabolite shows antitubercular activity
- In high-level INH resistance mutation in KatG gene occurs conversion
doesn’t occur drug is rendered ineffective!
- In such situations:
i. Avoid usage of INH!
ii. Ethionamide may be used(Since Ethionamide is effective in patients with high-level
INH resistance)!
Revised National Tuberculosis Control Programme: NATIONAL STRATEGIC PLAN FOR TUBERCULOSIS ELIMINATION 2017–2025.Available from
https://tbcindia.gov.in/WriteReadData/NSP%20Draft%2020.02.2017%201.pdf [Last accessed on January 22, 2019].
Tripathi K. Essentials of medical pharmacology. 8th ed. New Delhi: Jaypee Brothers Medical Publishers; 2018.
35. Extremely difficult to treat, necessitating use of Group-V drugs!
To prevent further progression of resistance stop standard MDR-regimen
immediately!
Since Group-V drugs are both costly & toxic an expert clinical panel may
decide on appropriate drug selection!
According to RNTCP(2016) guidelines:
- 7 drugs should be used in intensive phase(6-12 months)
- 6 drugs should be used in continuous phase(18 months)
Revised National Tuberculosis Control Programme: NATIONAL STRATEGIC PLAN FOR TUBERCULOSIS ELIMINATION 2017–2025.Available from
https://tbcindia.gov.in/WriteReadData/NSP%20Draft%2020.02.2017%201.pdf [Last accessed on January 22, 2019].
Tripathi K. Essentials of medical pharmacology. 8th ed. New Delhi: Jaypee Brothers Medical Publishers; 2018.
36. STANDARD RNTCP GUIDELINES FOR XDR-TB MANAGEMENT:
INTENSIVE PHASE(6-12 MONTHS) CONTINUOUS PHASE(18 MONTHS)
Capreomycin (1000 mg) Moxifloxacin (400 mg)
Moxifloxacin (400 mg) INH high dose (900 mg)
INH high dose (900 mg) PAS (12 g)
PAS (12 g) Clofazimine(200 mg)
Clofazimine(200 mg) Linezolid (600 mg)
Linezolid (600 mg) Amoxicillin/clavulanate (875+125 mg);
2 tablets in morning & 1 tablet in
evening.
Amoxicillin/clavulanate (875+125 mg);
2 tablets in morning & 1 tablet in
evening.
Revised National Tuberculosis Control Programme: NATIONAL STRATEGIC PLAN FOR TUBERCULOSIS ELIMINATION 2017–2025.Available from https://tbcindia.gov.in/WriteReadData/NSP%20Draft%2020.02.2017%201.pdf
[Last accessed on January 22, 2019].
Tripathi K. Essentials of medical pharmacology. 8th ed. New Delhi: Jaypee Brothers Medical Publishers; 2018.
N.B:
Add pyridoxine (100
mg/day) to the ATD
regimen mentioned in
left-hand side
37. BODY WEIGHT CATEGORY(in kg) INTENSIVE PHASE CONTINUATION PHASE
HRZE HRE
25-39 2 2
40-54 3 3
55-69 4 4
70 and above 5 5
• For intensive phase each tablet contains INH(75 mg), Rifampin(150 mg),
Pyrazinamide(400 mg) & Ethambutol(275 mg)
• For continuation phase each tablet contains INH(75 mg), Rifampin(150 mg)&
Ethambutol(275 mg)
Revised National Tuberculosis Control Programme: NATIONAL STRATEGIC PLAN FOR TUBERCULOSIS ELIMINATION 2017–2025.Available from https://tbcindia.gov.in/WriteReadData/NSP%20Draft%2020.02.2017%201.pdf [Last
accessed on January 22, 2019].
Tripathi K. Essentials of medical pharmacology. 8th ed. New Delhi: Jaypee Brothers Medical Publishers; 2018.
38. DRUG DAILY DOSE(in mg/kg)
INH 5 (4-6)
RIFAMPIN 10 (8-12)
PYRAZINAMIDE 25 (20-30)
ETHAMBUTOL 15 (15-20)
STREPTOMYCIN 15 (12-18)
PLEASE NOTE: If patient’s age > 50 years maximum dose of streptomycin will be 0.75
g/day!
Tripathi K. Essentials of medical pharmacology. 8th ed. New Delhi: Jaypee Brothers Medical Publishers; 2018.
40. Even though 1st line ATDs are well-tolerated minor ADRs may occur
resolved by symptomatic management, without necessitating drug
discontinuation
Examples:
1. In case of nausea, anorexia drug can be administered with small meals
2. In case of drowsiness ATD can be administered before bedtime
3. For Pyrazinamide-induced arthralgia analgesic NSAIDs may be opted
4. For INH-induced peripheral neuritis pyridoxine can be used
Tripathi K. Essentials of medical pharmacology. 8th ed. New Delhi: Jaypee Brothers Medical Publishers; 2018.
41. If severe reactions occur
Stop all drugs promptly
On resolution of reaction
Introduce drugs, one at a time(challenge with small doses & increasing dose every 3 days)
If offending drug is identified
Stop that drug
Reconstitute treatment regimen.
Revised National Tuberculosis Control Programme: NATIONAL STRATEGIC PLAN FOR TUBERCULOSIS ELIMINATION 2017–2025.Available from
https://tbcindia.gov.in/WriteReadData/NSP%20Draft%2020.02.2017%201.pdf [Last accessed on January 22, 2019].
Tripathi K. Essentials of medical pharmacology. 8th ed. New Delhi: Jaypee Brothers Medical Publishers; 2018.
42. Never reintroduce Rifampicin in cases of:
a. Hemolysis
b. Thrombocytopenia
c. Renal failure.
Discontinue ethambutol at 1st sign of optic neuritis!
Most common problem with ATDs: “Hepatotoxicity”
• Although 1st line ATDs(except streptomycin, ethambutol) are implicated hepatotoxicity
tends to aggravate, when 1st line ATDs are used as combination therapy
• If hepatitis develops stop all drugs allow reaction to subside
• In case of severe-TB focus on non-hepatotoxic drugs(Streptomycin + Ethambutol + one
FQ)
• Discontinued drugs should be started one at a time.
Tripathi K. Essentials of medical pharmacology. 8th ed. New Delhi: Jaypee Brothers Medical Publishers; 2018.
43. In general situations
Rifampin is introduced 1st
After 7 days
Introduce INH
If hepatitis recurs
Stop INH , and reconstitute the regimen.
If Rifampin & INH are tolerated
Do not restart pyrazinamide
Prolong treatment with “R”,”H” & “E” for 9 months.
Tripathi K. Essentials of medical pharmacology. 8th ed. New Delhi: Jaypee Brothers Medical Publishers; 2018.
44. If Rifampin is implicated in hepatitis
Give INH+ Ethambutol + Streptomycin (for 2 months)
Follow it up with combination of INH + Ethambutol (for 10 months)
If INH is implicated in Hepatitis
Give combination of Rifampin+ Ethambutol+ Pyrazinamide for 9 months.
Tripathi K. Essentials of medical pharmacology. 8th ed. New Delhi: Jaypee Brothers Medical Publishers; 2018.
46. DRUG CLASS: “Nitroimidazole”
MECHANISM OF ACTION:
- Delamanid shows bactericidal effects in 2 ways:
a. Drug blocks mycolic acid synthesis prevents bacteria from creating building
blocks important for cell-walls
b. Poisoning bacterial cells with NO(metabolite activity)
DRUG HALF-LIFE: 36 hours.
Revised National Tuberculosis Control Programme; GUIDELINES FOR USE OF DELAMANID IN THE TREATMENT OF DRUG RESISTANT TB IN INDIA 2018. Available from:
https://tbcindia.gov.in/showfile.php?lid=3343 [Accessed on January 22, 2019].
47. One of the 2 drugs(other one being Bedaquiline) developed for
treatment of MDR & XDR-TB
First approved by EMA in November 2014
Indicated to be used as part of an appropriate combination regimen
for Pulmonary MDR-TB, in adults & adolescents(6-17 years), in cases
of refractory or drug-intolerance TB cases
Revised National Tuberculosis Control Programme; GUIDELINES FOR USE OF DELAMANID IN THE TREATMENT OF DRUG RESISTANT TB IN INDIA 2018. Available from:
https://tbcindia.gov.in/showfile.php?lid=3343 [Accessed on January 22, 2019].
48. In conditions, where an effective MDR-TB regimen(containing 4 second line
drugs), in addition to pyrazinamide cannot be designed
Documented evidence of resistance to FQ/2nd line injectable (in addition to
MDR)
Conditions of poor clinical outcome, that include:
a. Drug intolerance
b. Contraindication
c. Extensive/advanced disease.
Revised National Tuberculosis Control Programme; GUIDELINES FOR USE OF DELAMANID IN THE TREATMENT OF DRUG RESISTANT TB IN INDIA 2018. Available from:
https://tbcindia.gov.in/showfile.php?lid=3343 [Accessed on January 22, 2019].
49. Children < 6 years
Pregnant & lactating women
Patients with repeated demonstrations of QT interval > 450-500 ms
History of TdP, or any other cardiac function abnormalities, etc.
Drug hypersensitivity or to its excipients
Revised National Tuberculosis Control Programme; GUIDELINES FOR USE OF DELAMANID IN THE TREATMENT OF DRUG RESISTANT TB IN INDIA 2018. Available from:
https://tbcindia.gov.in/showfile.php?lid=3343 [Accessed on January 22, 2019].
50. Treatment with delamanid should not be initiated in the following patients, unless “benefits
outweigh potential risks”:
a. Congenital prolongation of QTc interval
b. History of symptomatic arrhythmias
c. Pre-disposing cardiac conditions for arrhythmias(Severe HTN, LVH,etc.)
Monitor ECG before initiation , at day 15 of treatment & then monthly during full course of
treatment (In normal ECG baseline)
Frequent ECG monitoring warranted for QTc (450-500 ms)
Correct electrolyte imbalances(hypokalemia, hypocalcemia, hypomagnesemia) before
initiating therapy!!
Stop all QTc prolonging drugs, if QTc > 500 ms is observed!!
Revised National Tuberculosis Control Programme; GUIDELINES FOR USE OF DELAMANID IN THE TREATMENT OF DRUG RESISTANT TB IN INDIA 2018. Available from:
https://tbcindia.gov.in/showfile.php?lid=3343 [Accessed on January 22, 2019].
51. Delamanid prolongs QTc interval severely, if co-administered with:
a. Macrolides
b. FQs
c. TCAs
d. Triazole antifungals
e. Non-sedating antihistamines(astemizole, terfenadine)
f. Neuroleptics
g. Saquinavir, etc.
Revised National Tuberculosis Control Programme; GUIDELINES FOR USE OF DELAMANID IN THE TREATMENT OF DRUG RESISTANT TB IN INDIA 2018. Available from:
https://tbcindia.gov.in/showfile.php?lid=3343 [Accessed on January 22, 2019].
52. Use delamanid, only with appropriate combination regimen for
MDR-TB
Never add delamanid to a failing regimen!
Revised National Tuberculosis Control Programme; GUIDELINES FOR USE OF DELAMANID IN THE TREATMENT OF DRUG RESISTANT TB IN INDIA 2018. Available from:
https://tbcindia.gov.in/showfile.php?lid=3343 [Accessed on January 22, 2019].
53. As long as benefits outweigh risks delamanid may be used!
No studies available on efficacy of delamanid in CNS-TB!
Revised National Tuberculosis Control Programme; GUIDELINES FOR USE OF DELAMANID IN THE TREATMENT OF DRUG RESISTANT TB IN INDIA 2018. Available from:
https://tbcindia.gov.in/showfile.php?lid=3343 [Accessed on January 22, 2019].
54. For children delamanid may be used as 50 mg BD(6-11 years) and 100 mg
BD(12-17 years), for a duration of 24 weeks(6 months)
WEEK 0-24:
- Delamanid 100 mg (2 tabs of 50 mg); P/O; BD + Optimized background regimen
WEEK 25(From 7th month, till end of treatment):
- Continue with another 2nd line ATD(according to RNTCP guidelines)
- Delamanid can be taken with food to increase bioavailability!
Revised National Tuberculosis Control Programme; GUIDELINES FOR USE OF DELAMANID IN THE TREATMENT OF DRUG RESISTANT TB IN INDIA 2018. Available from:
https://tbcindia.gov.in/showfile.php?lid=3343 [Accessed on January 22, 2019].